Bone scan index at baseline as a tool for predicting hematologic toxicity in metastatic castration-resistant prostate cancer patients eligible for radium-223 treatment.
Kothari S, Sharif-Tabrizi A, Attwood K, Lamonica D, Levine E, George S. Bone scan index at baseline as a tool for predicting hematologic toxicity in metastatic castration-resistant prostate cancer patients eligible for radium-223 treatment. Journal Of Clinical Oncology 2017, 35: e16513-e16513. DOI: 10.1200/jco.2017.35.15_suppl.e16513.Peer-Reviewed Original ResearchBone scan indexHematologic toxicityScan indexHematologic parametersMetastatic castration-resistant prostate cancer patientsCastration-resistant prostate cancer patientsCastration-resistant prostate cancerRoswell Park Cancer InstituteRadium-223 treatmentRisk of cytopeniaPercent of patientsMedian Gleason scoreProstate cancer patientsALSYMPCA trialVisceral metastasesMedian ageSkeletal metastasesSuch patientsRadium-223Retrospective studyMore dosesCancer patientsGleason scorePredictive markerProspective validation